Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy
Preliminary Data from a Randomized Clinical Trial
Antibiotics (Basel). 2024 Apr 10;13(4):348. doi: 10.3390/antibiotics13040348.
ABSTRACT
Concomitant therapy (CT) and bismuth quadruple therapy (BQT) are recommended in areas with high clarithromycin resistance for Helicobacter pylori (H. pylori) eradication. We compared CT and BQT as the first lines of treatment in a randomized controlled trial.
Key Findings:
- Both CT and BQT were found to be equally effective in eradicating H. pylori in southern Italy, an area with high clarithromycin resistance.
- The success rate was 95.6% for CT and 100% for BQT.
- Both treatment regimens showed comparable safety.
Treatment Details:
- CT involved a combination of amoxicillin, clarithromycin, metronidazole, and pantoprazole, while BQT included PyleraTM capsules and pantoprazole.
- Both regimens lasted 10 days.
Side Effects:
- Side effects were recorded in 23.9% of patients in the CT group and 31.6% in the BQT group, with abdominal pain and diarrhea being the most common.
Conclusion:
Both CT and BQT are practical and valuable options for H. pylori eradication in areas with high clarithromycin resistance, such as southern Italy.
PMID: 38667024 | DOI: 10.3390/antibiotics13040348
Authors: Giuseppe Losurdo
